245 related articles for article (PubMed ID: 16611212)
1. Chemical biology and drug design: three-dimensional, dynamic, and mechanistic nature of two multidisciplinary fields.
Sawyer TK
Chem Biol Drug Des; 2006 Mar; 67(3):196-200. PubMed ID: 16611212
[No Abstract] [Full Text] [Related]
2. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
3. Molecular targets and cancer therapeutics.
Westwell AD
Drug Discov Today; 2004 Dec; 9(24):1042-4. PubMed ID: 15582792
[No Abstract] [Full Text] [Related]
4. Can cell systems biology rescue drug discovery?
Butcher EC
Nat Rev Drug Discov; 2005 Jun; 4(6):461-7. PubMed ID: 15915152
[TBL] [Abstract][Full Text] [Related]
5. Seeing is believing--visualizing drug delivery in vitro and in vivo.
Swartz H
Adv Drug Deliv Rev; 2005 Jun; 57(8):1085-6. PubMed ID: 15935867
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based vascular targeting of disease.
Rybak JN; Trachsel E; Scheuermann J; Neri D
ChemMedChem; 2007 Jan; 2(1):22-40. PubMed ID: 17154429
[TBL] [Abstract][Full Text] [Related]
7. Value of novelty?
Ma P; Zemmel R
Nat Rev Drug Discov; 2002 Aug; 1(8):571-2. PubMed ID: 12402497
[No Abstract] [Full Text] [Related]
8. The journal of pharmacy and pharmacology 2008.
Jones DS
J Pharm Pharmacol; 2009 Jan; 61(1):1-2. PubMed ID: 19126290
[No Abstract] [Full Text] [Related]
9. Initial compound selection for sequential screening.
Young SS; Lam RL; Welch WJ
Curr Opin Drug Discov Devel; 2002 May; 5(3):422-7. PubMed ID: 12058618
[TBL] [Abstract][Full Text] [Related]
10. The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
Lotze MT
Curr Opin Investig Drugs; 2003 Jun; 4(6):649-51. PubMed ID: 12901221
[No Abstract] [Full Text] [Related]
11. Therapeutic peptides: technological advances driving peptides into development.
Sato AK; Viswanathan M; Kent RB; Wood CR
Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837
[TBL] [Abstract][Full Text] [Related]
12. Target selection and pharma industry productivity: what can we learn from technology S-curve theory?
Brown D
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225
[TBL] [Abstract][Full Text] [Related]
13. Perspective from the founding editors. Preface.
Juliano R; Poste G; Tomlinson E
Adv Drug Deliv Rev; 2013 Jan; 65(1):3-4. PubMed ID: 22940253
[No Abstract] [Full Text] [Related]
14. Micro- and nano-fabricated implantable drug-delivery systems: current state and future perspectives.
Meng E; Sheybani R
Ther Deliv; 2014 Nov; 5(11):1167-70. PubMed ID: 25491666
[No Abstract] [Full Text] [Related]
15. Drug Discovery Technology 2003--seventh annual conference and exhibition. Science, business and IT for drug discovery II. 31 March-3 April 2003, Stuttgart, Germany.
Mackonochie M
IDrugs; 2003 May; 6(5):420-2. PubMed ID: 12841200
[No Abstract] [Full Text] [Related]
16. Applying advanced delivery technologies to enable and improve drug development. 8-9 December 2004, London, UK.
Uchegbu IF
IDrugs; 2005 Feb; 8(2):112-4. PubMed ID: 15696410
[No Abstract] [Full Text] [Related]
17. The pharmaceutical biochemistry group: where pharmaceutical chemistry meets biology and drug delivery.
Kalia YN; Perozzo R; Scapozza L
Chimia (Aarau); 2012; 66(5):313-9. PubMed ID: 22867543
[TBL] [Abstract][Full Text] [Related]
18. Vaccine manufacturing: challenges and solutions.
Ulmer JB; Valley U; Rappuoli R
Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
[TBL] [Abstract][Full Text] [Related]
19. Advances in recognitive, conductive and responsive delivery systems.
Bayer CL; Peppas NA
J Control Release; 2008 Dec; 132(3):216-21. PubMed ID: 18652857
[TBL] [Abstract][Full Text] [Related]
20. Interview with Haian Fu, PhD.
Fu H; Napper AD
Assay Drug Dev Technol; 2015 Jun; 13(5):249-53. PubMed ID: 26168060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
